Sable Therapeutics, a portfolio company of Turret Capital
Management, announces licensing agreement with Columbia University
NEW
YORK, Aug. 9, 2024 /PRNewswire/ -- Sable
Therapeutics, an innovative early stage drug development company
focused on pioneering fat reduction therapies, today announced an
exclusive worldwide licensing agreement with Columbia University. This collaboration will
advance a portfolio of novel polycation nanomedicines,
designated as SBL-001 and SBL-002, intended to treat visceral and
subcutaneous adiposity. Under the agreement, Sable
Therapeutics secures exclusive rights to develop and commercialize
the intellectual property developed at Columbia University by Drs. Kam Leong, Ph.D, Samuel Y. Sheng Professor of
Biomedical Engineering (in Systems Biology), and Li Qiang, Ph.D.,
Scientific Co-Founder of Sable Therapeutics and former Associate
Professor of Pathology and Cell Biology at Columbia University Vagelos College of Physicians
and Surgeons..
SBL-001 and SBL-002 are novel compounds designed to
significantly reduce fat cell volume. Importantly, these compounds
were uniquely engineered for selective uptake by adipose cells. Key
promising features of SBL-001 and SBL-002 include: (1) targeted
uptake by fat cells, (2) the ability to reduce fat cell volume by
as much as 70%, and (3) the potential to serve as a discrete drug
delivery system for other fat reducing agents, such as GLP 1's.
"We are thrilled to transition our research from the lab to
clinical development, providing a powerful and unique tool in the
fight against obesity," said Qiang.
"This exciting agreement sets Sable Therapeutics apart in both
the aesthetic and obesity-related markets. We are excited to
partner with Columbia and their team of experts as we continue to
develop novel assets for adipose reduction," said Daniel Chai, M.D., Managing Partner of Turret
Capital and Co-Founder of Sable Therapeutics.
ABOUT SABLE THERAPEUTICS
Sable Therapeutics is a drug development company developing
novel assets to target fat reduction. Sable Therapeutics'
commercial targets include reduction of visceral fat (obesity) and
subcutaneous fat (aesthetic indications). For more information,
visit us at www.sabletherapeutics.com.
View original
content:https://www.prnewswire.com/news-releases/sable-therapeutics-announces-exclusive-worldwide-licensing-agreement-with-columbia-university-to-develop-novel-polycation-nanomedicines-for-the-treatment-of-obesity-302219049.html
SOURCE Turret Capital Management